
LUCIA showed lower treatment burden and favorable safety, but DURAVYU did not meet the trial’s primary measure of visual acuity.
EyePoint said its investigational drug DURAVYU failed to meet the primary endpoint in LUCIA, its second Phase 3 trial for wet age-related macular degeneration. The study tested whether visual acuity changes were statistically non-inferior to on-label aflibercept.
The company said key secondary endpoints were met, including a 38% reduction in treatment burden. At Week 56, 52% of eyes were free of supplemental treatment, while 71% received zero or one supplemental injection. EyePoint also reported favorable safety with redosing.
EyePoint said it will conduct further analyses of LUCIA and pooled Phase 3 data to assess next steps for DURAVYU in wet AMD. The company’s Phase 3 trials of the drug for diabetic macular edema remain underway, with topline results expected in the fourth quarter of 2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.